Combinations to Dominate 2017 for Immunotherapy

Combinations to Dominate 2017 for Immunotherapy

AnnualMeeting-SITC2017

2 years
1,225 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Ezra E.W. Cohen, MD of University of California, San Diego states that in 2017, we will see more combination immuno-therapy for cancer treatment. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.
Up Next Autoplay
Viral Therapy Results Triggers Race to Complete Clinical Trials
Viral Therapy Results Triggers Race to Complete Clinical Trials
Category: Acute Lymphoblastic Leukemia
1,002 Views
AnnualMeeting-SITC2017 2 years
Viral Therapy May Prove to Be a Transformational Addition to Immuno-Oncology
Viral Therapy May Prove to Be a Transformational Addition to Immuno-Oncology
Category: Acute Lymphoblastic Leukemia
1,406 Views
AnnualMeeting-SITC2017 2 years
Recombinant Measles and Vesicular Stomatitis Virus are Ideal Adjunct to Checkpoint Immunotherapy
Recombinant Measles and Vesicular Stomatitis Virus are Ideal Adjunct to Checkpoint Immunotherapy
Category: Acute Lymphoblastic Leukemia
347 Views
AnnualMeeting-SITC2017 2 years
Stress Reducing Beta Blockers Combined With Immunotherapy May Increase Response Rates in Cancer Patients
Stress Reducing Beta Blockers Combined With Immunotherapy May Increase Response Rates in Cancer Patients
Category: Acute Lymphoblastic Leukemia
504 Views
AnnualMeeting-SITC2017 2 years
Retrospective Analysis Suggests Patients on Beta Blockers May Do Better on Immunotherapy Treatments
Retrospective Analysis Suggests Patients on Beta Blockers May Do Better on Immunotherapy Treatments
Category: Acute Lymphoblastic Leukemia
331 Views
AnnualMeeting-SITC2017 2 years
Higher Stress Levels in Mice Cause a Reduced Response Rate in Immunotherapy
Higher Stress Levels in Mice Cause a Reduced Response Rate in Immunotherapy
Category: Acute Lymphoblastic Leukemia
559 Views
AnnualMeeting-SITC2017 2 years
New Data Suggests Immunosenescence May Not Be a Factor in Immunotherapy Treatment
New Data Suggests Immunosenescence May Not Be a Factor in Immunotherapy Treatment
Category: Acute Lymphoblastic Leukemia
692 Views
AnnualMeeting-SITC2017 2 years
Pembrolizumab + Radiation Combination Shows Promise in Triple Negative Breast Cancer
Pembrolizumab + Radiation Combination Shows Promise in Triple Negative Breast Cancer
Category: Acute Lymphoblastic Leukemia
1,393 Views
AnnualMeeting-SITC2017 2 years
Microbiome As A Predictor for Immunotherapy
Microbiome As A Predictor for Immunotherapy
Category: Acute Lymphoblastic Leukemia
724 Views
AnnualMeeting-SITC2017 2 years
Docetaxel With or Without Plinabulin for Stage 3b or 4 Non-Small Cell Lung Cancer
Docetaxel With or Without Plinabulin for Stage 3b or 4 Non-Small Cell Lung Cancer
Category: Acute Lymphoblastic Leukemia
791 Views
AnnualMeeting-SITC2017 2 years